Abstract
Tamoxifen, an antiestrogen used in the treatment of breast cancer, was assessed for carcinogenic potential in the two-stage model of experimental hepatocarcinogenesis. Groups of female Fischer F344 rats were initiated with a non-necrogenic, subcarcinogenic dose of diethylnitrosamine (DEN; 10 mg/kg, po) and fed tamoxifen at a concentration of 250 mg per kg of AIN-76A diet for 6 or 15 months. The livers of these animals exhibited an increase in size and number of altered hepatic foci compared with those animals which were initiated with DEN but not exposed to tamoxifen. This finding indicates that tamoxifen may have a carcinogenic potential in the rat liver. After 6 months of treatment, neoplastic nodules were observed in 3/8 rats in the DEN-initiated, tamoxifen-treated group. In the initiated group provided with tamoxifen for 15 months, neoplastic nodules were observed in 7/8 rats and hepatocellular carcinomas in 3/8 rats. The serum level of tamoxifen in these rats was 200–300 ng/ml. The ratio of tamoxifen, 4-hydroxy tamoxifen, and N-desmethyl tamoxifen was 1:0.1:0.5-1 in the serum. When adjusted for age-related weight increases, the serum and liver levels of tamoxifen and its N-desmethyl metabolite did not change over the 15 months. In the rat liver, the level of tamoxifen and its N-desmethyl metabolite was 10-29 µg/g liver after 6 or 15 months of chronic dietary administration. The ratio of tamoxifen:4-hydroxy tamoxifen:N-desmethyl tamoxifen was 1:0.1:1.3-2.3 in the liver. Therefore, the liver had 20- to 30-fold more tamoxifen and 4-hydroxy tamoxifen and at least 100-fold more N-desmethyl tamoxifen than the serum (assuming 1 gram of tissue is equivalent to 1 ml of serum). These results indicate that tamoxifen is a promoting agent for the rat liver at serum levels found in patients given the usual therapeutic course of tamoxifen. The high concentrations of tamoxifen attained in the rat liver indicate that actions other than its known estrogenicity for liver could contribute to its promoting action. In addition, these results indicate that the pharmacodynamic differences in tamoxifen metabolism in rats and humans and at low versus high doses should be determined. Thus, the therapeutic indications for tamoxifen should be balanced by the potential risk it may present as a promoting agent in mammalian liver.
Similar content being viewed by others
References
Buchanan R, Blamey R, Durrant K, Howell A, Paterson A, Preese P, Smith D, Williams C, Wilson R: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4: 1326–1330, 1986
Cole M, Jones C, Todd I: A new antiestrogenic agent in late breast cancer: an early clinical appraisal of ICI 46,474. Br J Cancer 25: 270–275, 1971
Ingle J, Krook J, Green S, Kubista, Everson L, Ahmann D, Chang M, Bisel H, Windschitl H, Twito D, Pfeifle D: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178–185, 1986
Manni A, Pearson O: Anti-oestrogen-induced remissions in premenopausal women with Stage IV breast cancer: effects on ovarian culture. Cancer Treat Rep 64: 779–785, 1980
Sawka C, Pritchard K, Paterson D, Sutherland D: Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast cancer. Cancer Res 46: 3152–3156, 1986
Tormey DC, Simon R, Lippman M, Bull J, Myers C: Evaluation of tamoxifen in advanced breast cancer: a progress report. Cancer Treat Rep 60: 1451–1459, 1976
Ward HWC: Antiestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J i: 13–14, 1973
Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocrin Rev 11: 578–610, 1990
Jordan VC: Long-term tamoxifen therapy for breast cancer. In: DeVita VT, Hellman S, Rosenberg S (eds) Important Advances in Oncology. Lippincott, Philadelphia, 1989, pp 179–192
Early Breast Trials Cooperative Group: Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 319: 1681–1692, 1988
Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 4: 297–302, 1984
Delozier T, Julien J, Juret P, Veyret C, Couette J-E, Graic Y, Ollivier J-M, de Ranieri E: Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial. Breast Cancer Res Treat 7: 105–110, 1986
Fisher B, Brown A, Wolmark N, Redmond C, Wickerham DL, Wittliff J, Dimitrov N, Legault-Poisson S, Schipper H, Prager D: Prolonging tamoxifen therapy for primary breast cancer. Ann Intern Med 106: 649–654, 1987
Falkson H, Gray R, Wolberg W, Gilchrist K, Harris J, Tormey D, Falkson G: Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol 8: 599–607, 1990
Diver JMJ, Jackson IM, Fitzgerald JD: Tamoxifen and nonmalignant indications. Lancet i: 733, 1986
Fentiman IS, Powles TJ: Tamoxifen and benign breast problems. Lancet ii: 1070–1072, 1987
Prentice R: Tamoxifen as a potential preventative agent in healthy postmenopausal women. J Natl Cancer Inst 82: 12–13, 1990
Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Coutre J, Dimitrov N, Wolmark N, Wickerham DL, Fisher E, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman M, Farrar W, Evans J, Lickley HL, Ketner Met al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 320: 479–484, 1989
Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T, Askergren J, Rutquist LE, Silfversward C, Somell A, Wilking N, Hjalmar ML: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet i: 117–120, 1989
Nayfield S, Karp J, Ford L, Dorr F, Kramer B: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83: 1450–1459, 1991
Powles T, Tillyer C, Jones A, Ashley S, Treleaven J, Davey J, McKinna J: Prevention of breast cancer with tamoxifen -an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 26: 680–684, 1990
Jordan VC: Long-term tamoxifen therapy to control or to prevent breast cancer: laboratory concept to clinical trials. In: Hankins WD, Puett D (eds) Hormones, Cell Biology, and Cancer: Perspectives and Potentials. AR Liss Inc., New York, 1988, pp 105–123
Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Therap Pharm 25: 127–205, 1984
Jordan VC, Allen KE, Dix CJ: Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64(6-7): 745–759, 1980
Jordan VC: The pharmacology of antiestrogens. In: Rose DP (ed) CRC-Endocrinology of Cancer 3. CRC Press, Boco Raton FL, 1982, pp 129–179
Cuzick J, Allen D, Baum M, Barrett J, Clark G, Kakkar V, Melissari E, Moniz C, Moore J, Parsons V, Pemberton K, Pitt P, Richmond W, Houghton J, Riley D: Long term effects of tamoxifen. Biological effects of tamoxifen working group. Europ J Cancer 29A: 15–21, 1993
Helgason S, Wilking N, Carlstron K, Damber M-G, von Schoultz B: A comparative study of the estrogenic effects of tamoxifen and 17β estradiol in postmenopausal women. J Clin Endocrin Metab 54: 404–408, 1982
Jordan VC: Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Treat 15: 125–136, 1990
Love R, Newcomb P, Wiebe D, Surawicz T, Jordan V, Carbone P, DeMets D: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node negative disease. J Natl Cancer Inst 82: 1327–1332, 1990.
Fornander T, Rutqvist L, Sjoberg, H, Blomqvist L, Mattison A, Glas U: Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 8: 1019–1024, 1990
Gusberg SB: Tamoxifen for breast cancer: associated endometrial cancer. Cancer 65: 1463–1464, 1990
Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic nude mouse. Cancer Res 48: 812–815, 1988
Tamoxifen for node negative breast cancer. FDA Drug Bulletin 20: 5, 1990
Hirsamaki P, Hirsamaki Y, Nieminen L, Payne BJ: Tamoxifen induces hepatocellular carcinoma in rat liver: a one year study with two antiestrogens. Arch Toxicol 67: 49–54, 1993
Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP: The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14: 315–317, 1993
Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T: Two year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53: 3919–3924, 1993
Gau TC: Open letter concerning Nolvadex. Stuart Pharmaceuticals, 1987
Sasco A: Tamoxifen: a carcinogen as a preventive agent. Cancer J 4: 217–218, 1991
Davidson N: Tamoxifen - panacea or Pandora's box? N Engl J Med 326: 885–886, 1992
Williams G, Iatropoulos M, Hard G: Long-term prophylactic use of tamoxifen: is it safe? Europ J Cancer Prev 1: 386–387, 1992
Fugh-Berman A, Epstein S: Should healthy women take tamoxifen? N Engl J Med 22: 1596, 1992
Mishkin SY, Farber E, Ho RK, Mulay S, Mishkin S: Evidence for the hormone dependency of hepatic hyperplastic nodules: inhibition dependency of malignant transformation after endogenous 17β estradiol and tamoxifen. Hepatology 3: 308–316, 1983
Kohigashi K, Fukuda Y, Imura H: Inhibitory effect of tamoxifen on DES-promoted hepatic tumorigenesis in male rats and its possible mechanism of action. Gann 79: 1335–1339, 1988
Taper HS: The effect of estradiol-17-phenylpropionate and estradiol benzoate on N-nitrosomorpholine-induced liver carcinogenesis in ovariectomized female rats. Cancer 42: 462–467, 1978
Yager JD, Yager R: Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res 40: 3680–3685, 1980
Wanless IR, Medline A: Role of estrogens as promoters of hepatic neoplasia. Lab Invest 46(3): 313–320, 1982
Edmonson HA, Reynolds TB, Henderson B: Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 86: 180–182, 1977
Kneiffel MA, Katzenellenbogen BS: Comparative effects of estrogen and antiestrogens on plasma renin substrate levels and hepatic estrogen receptors in the rat. Endocrinology 108: 595–652, 1981
Kendall ME, Rose DP: The effects of diethylstilbesterol, tamoxifen, and toremifene on estrogen inducible hepatic protein and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 114: 127–131, 1992
Sakai F, Cheix F, Clavel M, Colon J, Mayer M, Pannata E, Saez S: Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrin 76: 219–226, 1978
Szamel I, Vincze B, Hindy I, Hermann I, Borvendeg J, Eckhardt S: Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer. Oncology 43: 7–11, 1986
Popper H, Selikoff IJ, Maltoni C, Squire RA, Thomas LB: Comparison of neoplastic hepatic lesions in man and experimental animals. In: Hiatt HH, Watson JD, Winsten JA (eds) Origins of Human Cancer Book C. Human Risk Assessment. Cold Spring Harbor Laboratory, New York, 1977, 1359–1382
Pitot HC: Principles of carcinogenesis: chemical. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer-Principles and Practice of Oncology. Vol 1, 3rd edition, JB Lippincott Co, Philadelphia, 1989, pp 116–135
Pitot HC, Barsness L, Goldsworthy T, Kitagawa T: Biochemical characterization of stages of hepatocarcinogenesis after a single dose of diethylnitrosamine. Nature (Lond) 271: 456–458, 1978
Goldsworthy T, Pitot HC: An approach to the development of a short-term whole animal bioassay to distinguish initiating (incomplete) carcinogens, complete carcinogens, and noncarcinogens in the rat liver. - J Toxic Environ Health 16: 389–402, 1986
Scherer E, Emmelott P: Kinetics of induction and growth of precancerous liver-cell foci, and liver tumor formation by DEN in rats. Europ J Cancer 11: 689–696, 1975
Peraino C, Staffeldt E, Carnes B, Vessilinovitch S: Characterization of histochemically detectable altered hepatic foci and their relationship to hepatic tumorigenesis in rats treated once with DEN or B(a)P within one day of birth. Cancer Res 44: 3340–3347, 1984
Hendrich S, Campbell HA, Pitot HC: Quantitative stereological evaluation of four histological markers of altered foci in multistage hepatocarcinogenesis in the rat. Carcinogenesis 8: 1245–1250, 1987
Campbell HA, Pitot HC, PotterVR, Laishes BA: Application of quantitative stereology to the evaluation of enzyme-altered foci in rat liver. Cancer Res 42: 465–472, 1982
Campbell HA, Xu YD, Hanigan MH, Pitot HC: Application of quantitative stereology to the evaluation of phenotypically heterogeneous enzyme-altered foci in the rat liver. J Natl Cancer Inst 76: 751–767, 1982
Squire RA, Levitt: Workshop on classification of specific hepatocellular lesions in the rat. Cancer Res 35: 3214–3223, 1975
Hsu S, Raine L, Fanger H: A comparative study of the peroxidase-antiperoxidase method and an avidin biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 75: 734–738, 1981
Bondi A, Chieregatti G, Eusabi V, Fulcheri E, Bussolatti G: The use of β-galactosidase as a tracer in immunocytochemistry. Histochemistry 76: 153–158, 1982
Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC: Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19: 36–43, 1991
Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Europ J Cancer 26: 883–888, 1990
Brown RR, Bain RR, Jordan VC: Determination of tamoxifen and metabolites in human serum by high pressure liquid chromatography with post column fluorescence activation. J Chromat 272: 351–358, 1983
Etienne M, Milano G, Fischel J, Frenay M, Francois E, Formento J, Gioanni J, Namer M: Tamoxifen metabolism: pharmacokinetic andin vitro study. Br J Cancer 60: 30–35, 1989
Lien E, Solheim E, Ueland P: Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. Cancer Res 51: 4837–4844, 1991
Bratherton D, Brown C, Buchanan R, Hall V, Pillers E, Wheeler T, Williams C: A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 50: 199–205, 1984
Watanabe M, Tanaka H, Koizumi H, Tanimoto Y, Torii R, Yanagita T: General toxicity studies of tamoxifen in mice and rats. Jitchuken Zenrinsko Kenkyuko 6: 1–36, 1980
Harper MJK, Walpole AL: Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 21: 87, 1966
Dragan YP, Sargent L, Xu YD, Xu YH, Pitot HC: The initiation-promotion-progression model of rat hepatocarcinogenesis. Proc Soc Exp Biol Med 202: 16–24, 1993
Pitot HC, Goldsworthy TL, Moran S, Keenan W, Glauert HP, Maronpot RR, Campbell HA: A method to quantitate the relative initiating and promoting potencies of hepatocarcinogenic agents in their dose-response relationships to altered hepatic foci. Carcinogenesis 8: 1491–1499, 1987
Metzler M, Schiffmann D: Structural requirements for thein vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene type antiestrogens. Am J Clinical Oncol 14: S30-S35, 1991
Han X, Liehr J: Induction of covalent adducts in rodents by tamoxifen. Cancer Res 52: 1360–1363, 1992
Mani C, Kupfer D: Cytochrome P450 mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver; possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res 51: 6052–6058, 1991
White INH, de Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH: Genotoxic potential of tamoxifen and analogues in female Fischer F244/n rats, DBA/2 and C57BL/6 mice, and human MCL-5 cells. Carcinogenesis 13: 2197–2203, 1992
Tucker MJ, Adam HK, Patterson JS: Tamoxifen. In: Laurence DR, McLean AEM, Wetherall (eds) Safety Testing of New Drugs. Laboratory Predictions and Clinical Performance. Academic Press, London, 1984, pp 125–161
Maltoni C, Pinto C, Paladini G: Project of experimental bioassays on chemoprevention agents performed at the Bologna Institute of Oncology: Report on tamoxifen control of spontaneous mammary tumors in Sprague-Dawley rats. Cancer Invest 6: 643–658, 1988
Hirsimaki P, Hirsamaki Y, Nieminen L: The effects of tamoxifen citrate and toremifene citrate on the ultrastructure of the rat liver. Inst Phys Conf Ser 93: 235–236, 1988
Yager JD, Roebuck BD, Paluscyk TL, Memoli VA: Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase positive foci in female rats. Carcinogenesis 7: 2007–2014, 1986
Ghia M, Mereto E: Induction and promotion of γglutamyltranspeptidase-positive foci in the livers of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations. Cancer Lett 46: 195–202, 1989
Dragan YP, Xu YH, Pitot HC: Tumor promotion as a target of estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prevent Med 20: 15–26, 1991
Dragan YP, Rizvi TA, Xu YH, Hully JR, Maronpot RR, Campbell HA, Pitot HC: An initiation-promotion assay in rat liver as a potential complement to the two-year bioassay. Fund Appl Toxicol 16: 525–547, 1991
Board of Scientific Advisors: Report of the NTP Ad Hoc Panel on chemical carcinogenesis testing and evaluation. NTP 248-254; 264-266, 1984
Lüllmann H, Lüllmann-Rauch R: Tamoxifen-induced generalized lipidosis in rats subchronically treated with high doses. Toxicol Appl Pharmacol 61: 138–146, 1981
Hendrich S, Glauert H, Pitot H: Dietary effects on initiation and promotion of hepatocarcinogenesis in the rat. J Cancer Res Clin Oncol 114: 49–157, 1988
Hendrich S, Glauert H, Pitot H: A semipurified diet that suppresses phenobarbital promotion of hepatocarcinogenesis in the rat. Nutr Cancer 12: 249–258, 1988
Juedes M, Kupfer D: The role of P450c in the formation of a reactive intermediate of chlorotrianisene (TACE) by hepatic microsomes from methylcholanthrene treated rats. Drug Metabol Dispos 18: 131–137, 1990
Juedes M, Bulger W, Kupfer D: Monooxygenase mediated activation of chlorotrianisene (TACE) in covalent binding to rat hepatic microsomal protein. Drug Metabol Dispos 15: 786–793, 1987
Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F: Identification of the cytochrome IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41: 1911–1919, 1991
Ericksson L, Ahluwalia M, Spiewak J, Lee G, Sarma DSR, Roomi M, Farber E: Distinctive biochemical pattern associated with resistance to hepatocytes in hepatocyte nodules during liver carcinogenesis. Environ Health Perspect 49: 171–174, 1993
Nuwaysir E, Dragan Y, Pitot H: Tamoxifen induces hepatic cytochrome P450IIB1 and IIB2 in F344 rats. Toxicologist 12: A917, 1992
White INH, Davies A, Smith LL, Dawson S, de Matteis F: Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the liver of female rats and mice. Biochem Pharmacol 45: 21–30, 1993
Jones CR, Lubett RA: Induction of a pleiotropic response by phenobarbital and related compounds. Response in various inbred strains of rat, response in various species, and the induction of aldehyde dehydrogenase in Copenhagen rats. Biochem Pharmacol 44: 1651–1660, 1992
Dannan G, Guengerich FP: Immunochemical comparison and quantitation of microsomal flavin-containing monooxygenases in various hog, mouse, rat, rabbit, dog, and human tissues. Molec Pharmacol 22: 787–794, 1982
Board of Scientific Advisors: Report of the NTP Ad Hoc Panel on chemical carcinogenesis testing and evaluation. NTP 138-149, 1984
Shi Y, Yager J: Enhancement in rats by the liver tumor promoter ethinyl estradiol of a serum factor(s) which is stimulatory for hepatocyte DNA synthesis. Biochem Biophys Res Commun 160: 154–161, 1989
Butta A, MacLennan, Flanders K, Sacks N, Smith I, McKinna A, Dowsett M, Wakefield L, Sporn M, Baum M, Coletta A: Induction of TGFβ in human breast cancerin vivo following tamoxifen treatment. Cancer Res 52: 4261–4264, 1992
Huynh H, Tetenes E, Wallace L, Pollak M:In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res 53: 1727–1730, 1993
Koch K, Lu X, Brenner D, Fey G, Martinez-Conde A, Leffert H: Mitogens and hepatocyte growth controlin vivo andin vitro. In Vitro Cell Develop 26: 1011–1023, 1990
Bruning P, Bonfer J, Hart A, Jong-Bakker M, Linders D, van Loon J, Nooyen W: Tamoxifen, serum lipoproteins, and cardiovascular risk. Br J Cancer 58: 497–499, 1988
Weiss D, Gurpide E: Nongenomic effects of estrogens and antiestrogens. J Steroid Biochem 31: 671–676, 1988
Osborne C, Boldt D, Clark G, Trent J: Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 4837–4844, 1983
Francavilla A, Polimeno L, Dileo A, Barone M, Ove P, Coetzee M, Eagon P, Makowka L, Ambrosino G, Mazzaferro V, Starzl T: The effect of estrogen and tamoxifen on hepatocyte proliferationin vivo andin vitro. Hepatology 9: 614–620, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dragan, Y.P., Fahey, S., Street, K. et al. Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res Tr 31, 11–25 (1994). https://doi.org/10.1007/BF00689673
Issue Date:
DOI: https://doi.org/10.1007/BF00689673